Marco Filetti | Ricerc@Sapienza

Publications

Title	Published on	Year
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study	THE LANCET ONCOLOGY	2021
10P Family history of cancer correlates with improved outcome from immunotherapy in NSCLC independent of somatic DNA damage response gene status	ANNALS OF ONCOLOGY	2021
966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy	ANNALS OF ONCOLOGY	2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study	JAMA ONCOLOGY	2021
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy	EUROPEAN JOURNAL OF CANCER	2021
Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma	ENDOCRINE	2020
Correction to. Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma	ENDOCRINE	2020
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification	ANNALS OF ONCOLOGY	2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study	EUROPEAN JOURNAL OF CANCER	2020
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden	ANNALS OF ONCOLOGY	2020
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes	CLINICAL LUNG CANCER	2020
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases	FRONTIERS IN ONCOLOGY	2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2020
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes	CLINICAL & TRANSLATIONAL ONCOLOGY.	2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events	EUROPEAN JOURNAL OF CANCER	2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study	ONCOIMMUNOLOGY	2020
Health as a human right, the right to life and the freedom to choose	RECENTI PROGRESSI IN MEDICINA	2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%	CANCER IMMUNOLOGY, IMMUNOTHERAPY	2020
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study	LUNG CANCER	2020

Progetti di Ricerca

Evaluation of MYC expression as a predictor of response to chemo-immunotherapy treatment in small cell lung cancer.
Circulating pro inflammatory cytokines levels as a prognostic role in immunotherapy DLT and survival in Stage IV NSCLC patients undergone 1st and 2nd line Immunotherapy.
Double Trouble. Impact of a double EGFR mutation in clinical outcomes for first line therapy in advanced NSCLC.